DDInter1628 DDInter1733
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Ruxolitinib {u} (Compound) binds {v} (Gene) MAP3K3
MAP3K3 {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Ruxolitinib {u} (Compound) binds {v} (Gene) JAK2
JAK2 {u} (Gene) is bound by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Suvorexant
Ruxolitinib {u} (Compound) downregulates {v} (Gene) EML3
EML3 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Imatinib
Imatinib {u} may lead to a major life threatening interaction when taken with {v} Suvorexant
Ruxolitinib {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Ruxolitinib {u} (Compound) downregulates {v} (Gene) GLRX
GLRX {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Ruxolitinib {u} (Compound) downregulates {v} (Gene) PIGB
PIGB {u} (Gene) is downregulated by {v} (Compound) Fluconazole
Fluconazole {u} may lead to a major life threatening interaction when taken with {v} Suvorexant
Ruxolitinib {u} (Compound) downregulates {v} (Gene) NUPR1
NUPR1 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Suvorexant
Ruxolitinib {u} (Compound) upregulates {v} (Gene) DNTTIP2
DNTTIP2 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Ruxolitinib (Compound) binds MAP3K3 (Gene) and MAP3K3 (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Ruxolitinib (Compound) binds JAK2 (Gene) and JAK2 (Gene) is bound by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Suvorexant
Ruxolitinib (Compound) downregulates EML3 (Gene) and EML3 (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Imatinib (Compound) and Imatinib may lead to a major life threatening interaction when taken with Suvorexant
Ruxolitinib (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Ruxolitinib (Compound) downregulates GLRX (Gene) and GLRX (Gene) is downregulated by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Ruxolitinib (Compound) downregulates PIGB (Gene) and PIGB (Gene) is downregulated by Fluconazole (Compound) and Fluconazole may lead to a major life threatening interaction when taken with Suvorexant
Ruxolitinib (Compound) downregulates NUPR1 (Gene) and NUPR1 (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Suvorexant
Ruxolitinib (Compound) upregulates DNTTIP2 (Gene) and DNTTIP2 (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant